Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2411311rdf:typepubmed:Citationlld:pubmed
pubmed-article:2411311lifeskim:mentionsumls-concept:C0042666lld:lifeskim
pubmed-article:2411311lifeskim:mentionsumls-concept:C0022564lld:lifeskim
pubmed-article:2411311lifeskim:mentionsumls-concept:C0003320lld:lifeskim
pubmed-article:2411311lifeskim:mentionsumls-concept:C1268443lld:lifeskim
pubmed-article:2411311lifeskim:mentionsumls-concept:C0021770lld:lifeskim
pubmed-article:2411311lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:2411311pubmed:issue3lld:pubmed
pubmed-article:2411311pubmed:dateCreated1985-10-7lld:pubmed
pubmed-article:2411311pubmed:abstractTextAntibody 3-40 defines a 35- to 40-kd surface antigen present on T lymphoblastic leukemia (T-ALL) cells that is absent on normal hematopoietic cells (Naito et al, Blood 62:852, 1983). Using immunoblot analysis of cytoskeletal proteins and indirect immunofluorescence of cell lines treated with various cytoskeletal inhibitors, in this report we have demonstrated that antibody 3-40 also identifies vimentin intermediate filaments (IMF) within the HSB-2 (T-ALL) cell line as well as in normal thymocytes, peripheral blood mononuclear cells, and human and rodent fibroblast cell lines. Cross-reactivity with several keratin subclasses was demonstrated in both human and rodent epithelial cell lines, human thymus, and skin. In addition, we have shown that antibody 3-40 defined a 39-kd intracellular IMF-associated protein in HSB-2 cells, epithelial and fibroblast cell lines. This IMF-associated protein may be selectively expressed on the surface of human T cells during malignant transformation.lld:pubmed
pubmed-article:2411311pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2411311pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2411311pubmed:languageenglld:pubmed
pubmed-article:2411311pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2411311pubmed:citationSubsetAIMlld:pubmed
pubmed-article:2411311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2411311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2411311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2411311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2411311pubmed:statusMEDLINElld:pubmed
pubmed-article:2411311pubmed:monthSeplld:pubmed
pubmed-article:2411311pubmed:issn0006-4971lld:pubmed
pubmed-article:2411311pubmed:authorpubmed-author:HaynesB FBFlld:pubmed
pubmed-article:2411311pubmed:authorpubmed-author:DuPontBBlld:pubmed
pubmed-article:2411311pubmed:authorpubmed-author:NaitoKKlld:pubmed
pubmed-article:2411311pubmed:authorpubmed-author:HoWWlld:pubmed
pubmed-article:2411311pubmed:authorpubmed-author:PalkerT JTJlld:pubmed
pubmed-article:2411311pubmed:authorpubmed-author:HardenE AEAlld:pubmed
pubmed-article:2411311pubmed:authorpubmed-author:LasterA JAJlld:pubmed
pubmed-article:2411311pubmed:issnTypePrintlld:pubmed
pubmed-article:2411311pubmed:volume66lld:pubmed
pubmed-article:2411311pubmed:ownerNLMlld:pubmed
pubmed-article:2411311pubmed:authorsCompleteYlld:pubmed
pubmed-article:2411311pubmed:pagination642-8lld:pubmed
pubmed-article:2411311pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:2411311pubmed:meshHeadingpubmed-meshheading:2411311-...lld:pubmed
pubmed-article:2411311pubmed:meshHeadingpubmed-meshheading:2411311-...lld:pubmed
pubmed-article:2411311pubmed:meshHeadingpubmed-meshheading:2411311-...lld:pubmed
pubmed-article:2411311pubmed:meshHeadingpubmed-meshheading:2411311-...lld:pubmed
pubmed-article:2411311pubmed:meshHeadingpubmed-meshheading:2411311-...lld:pubmed
pubmed-article:2411311pubmed:meshHeadingpubmed-meshheading:2411311-...lld:pubmed
pubmed-article:2411311pubmed:meshHeadingpubmed-meshheading:2411311-...lld:pubmed
pubmed-article:2411311pubmed:meshHeadingpubmed-meshheading:2411311-...lld:pubmed
pubmed-article:2411311pubmed:meshHeadingpubmed-meshheading:2411311-...lld:pubmed
pubmed-article:2411311pubmed:meshHeadingpubmed-meshheading:2411311-...lld:pubmed
pubmed-article:2411311pubmed:meshHeadingpubmed-meshheading:2411311-...lld:pubmed
pubmed-article:2411311pubmed:meshHeadingpubmed-meshheading:2411311-...lld:pubmed
pubmed-article:2411311pubmed:meshHeadingpubmed-meshheading:2411311-...lld:pubmed
pubmed-article:2411311pubmed:meshHeadingpubmed-meshheading:2411311-...lld:pubmed
pubmed-article:2411311pubmed:year1985lld:pubmed
pubmed-article:2411311pubmed:articleTitleAntibody against T lymphoblastic leukemia-associated antigen (3-40) identifies vimentin and keratin intermediate filaments in normal cells.lld:pubmed
pubmed-article:2411311pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2411311pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed